Detalhe da pesquisa
1.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell;
174(3): 758-769.e9, 2018 07 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30033370
2.
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell;
175(3): 889, 2018 10 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30340047
3.
Impact of PSMA PET on Prostate Cancer Management.
Curr Treat Options Oncol;
25(2): 191-205, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38270802
4.
LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).
BJU Int;
132(1): 65-74, 2023 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36797449
5.
Multimodality Therapies for Localized Prostate Cancer.
Curr Oncol Rep;
25(3): 221-229, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36723856
6.
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
Lancet Oncol;
23(2): 304-316, 2022 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35051385
7.
Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol;
20 Suppl 9(5): 1-20, 2022 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35579577
8.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol;
22(8): 1115-1125, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34246328
9.
Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer.
J Biol Chem;
295(50): 17169-17186, 2020 12 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33028635
10.
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
Eur J Nucl Med Mol Imaging;
48(2): 501-508, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32808077
11.
Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay.
Proc Natl Acad Sci U S A;
115(40): 9986-9991, 2018 10 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30224472
12.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Lancet Oncol;
20(9): 1286-1294, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31375469
13.
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.
Med Res Rev;
39(3): 910-960, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30565725
14.
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
BMC Cancer;
19(1): 291, 2019 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30935383
15.
How patient characteristics can guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol;
20 Suppl 9(5): 9-12, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35579579
16.
Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
Clin Adv Hematol Oncol;
20 Suppl 9(5): 16-17, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35579581
17.
Highlights in prostate cancer from the 2021 European Society for Medical Oncology Congress and the 2021 American Urological Association Meeting: commentary.
Clin Adv Hematol Oncol;
19 Suppl 23(11): 19-23, 2021 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35289808
18.
Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice.
Biomolecules;
14(1)2024 Jan 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38254705
19.
RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med;
2024 Apr 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38637143
20.
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res;
30(8): 1488-1500, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38300720